To help foster more industry-patient group partnerships across the industry, BayBio recently completed the first national assessment of such collaborations — to extract what is working well and what may lead to failure — from a strong sample set of case studies and relationships. The purpose of the study was to highlight the benefits of partnership, identify opportunities for growth, share best practices, and describe key pitfalls to avoid. Through this work, BayBio intends to provide a roadmap – both for life science companies and patient groups – of how to explore, form and navigate successful outcomes from the pioneers who led the way.
Biomedical companies that can harness the power of patient groups will get medicines, devices and diagnostics to market faster, cheaper and smarter, helping patients and rewarding investors. Foundations bring urgency, intelligence and resources like patient data and biospecimens, preclinical models, and trial and recruitment support that can be essential to progressing key steps in the development process. In short, they can influence research.
BIO International Convention: Panel Discussion with Industry and Foundation Leaders
June 25, 2014
San Diego, CA
Disease foundations are playing an increasingly important role in bringing treatments to patients and to market. In these challenging economic times, disease foundations are playing a larger role in the strategic funding of early, innovative drug discovery programs. Their unique expertise in specific disease areas can be incredibly valuable in developing and disseminating new research tools, technologies and clinical protocols. Plus, their understanding of standard of care and patient needs, as well as their access to clinical thought leaders and patients, can enhance and accelerate clinical development of new treatments. Industry and foundation executives share what they view as the key opportunities and challenges for industry-foundation collaborations.
Successful Public-Private Partnerships: A National Survey and Leadership Perspectives Whitepaper
Please complete this contact form to access the report and the executive summary:
In collaboration with: